Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM5614 plus nivolumab vs placebo plus nivolumab in unresectable PD-1–refractory melanoma
jRCT2021240049Phase 3Active, not recruiting
- Sponsor
- Renascience
- Start
- Feb 2025
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing TM5614 plus nivolumab with Placebo plus nivolumab (2 arms). Primary endpoint: Overall survival. Started Feb 2025; status: active, not recruiting.
02
Drugs
TM5614
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2021240049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240049.